ARF6 and neoplasm: Indeed, genetic activation of ARF6 dramatically reduced apoptosis after 48 hours of vemurafenib (Fig. 4c), whereas silencing of Arf6 significantly increased apoptosis induced by vemurafenib (Fig S3b), consistent with a role for ARF6 in early tumor cell survival during targeted therapy.